Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Zacks.com on MSN4d
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the ...
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
Zacks.com on MSN4d
INCY vs. VRTX: Which Stock Is the Better Value Option?
Incyte has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that INCY likely has seen a stronger improvement to ...